Long-term adverse events and survival of patients with neuroendocrine neoplasms (NEN) receiving peptide receptor radioligand therapy (PRRT) using 225Ac-and 225Ac-/177Lu-labeled (TANDEM) antagonist DOTA-LM3: A retrospective analysis

被引：0

|

作者：

Perrone, Elisabetta ^{[1
,2
]}

Mishra, Aditi ^{[1
]}

Eismant, Aleksandr ^{[1
]}

Ghai, Kriti ^{[1
]}

Greifenstein, Lukas ^{[1
]}

Baum, Richard P. ^{[1
]}

机构：

[1] CURANOSTICUM Wiesbaden Frankfurt, Frankfurt, Germany

[2] Univ Cattolica Sacro Cuore, Inst Nucl Med, Rome, Italy

来源：

JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

242083

引用

收藏

页数：3

相关论文

共 3 条

[1] Peptide receptor radiopeptide therapy (PRRT) using the 225Actinium-and 225Actinium/177Lutetiumlabelled (TANDEM) somatostatin-receptor (SSTR) antagonist DOTA-LM3 in patients with neuroendocrine neoplasms (NEN): A retrospective study concerning safety and survival
Perrone, E.
Mishra, A.
Eismant, A.
Ghai, K.
Greifenstein, L.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S125 - S125
[2] 225Actinium and combined 225Actinium/177Lutetiumlabelled (TANDEM) PSMA radioligand therapy (PRLT) in patients with metastatic castration resistant prostate cancer (mCRPC): A retrospective study on long-term adverse events and survival
Perrone, E.
Mishra, A.
Eismant, A.
Ghai, K.
Greifenstein, L.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S360 - S360
[3] Peptide targeted radioligand therapy (PTRT) using Fibroblast Activation Protein (FAP) labelled with 225Actinium as mono- or TANDEM-therapy: A retrospective analysis of long-term safety and survival in patients with progressive, end-stage malignancies
Perrone, E.
Mishra, A.
Eismant, A.
Ghai, K.
Greifenstein, L.
Baum, R. P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S35 - S35